|Bid||50.50 x 200|
|Ask||54.50 x 300|
|Day's Range||52.10 - 54.06|
|52 Week Range||26.26 - 57.57|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. The net inflows of $2.76 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing.
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. The net inflows of $2.56 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing.
Sarepta Therapeutics (SRPT) has moved to solidify its position as the leading company in the treatment of Duchenne muscular dystrophy (DMD) with the recent announcement of three new clinical trials. Sarepta CEO Doug Ingram called the Anthem move “a fantastic result for children with DMD” in a Barron’s interview Thursday. The selloff probably reflects hedging activity by convertible arbitragers who purchased the big Sarepta convertible.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
The U.S. Food and Drug Administration approved Sarepta for Duchenne, a degenerative disease that mostly affects young boys, last year despite questions from experts and its own reviewers about the efficacy of the drug. An Anthem spokeswoman said its medical policy committee had reviewed information presented at recent scientific meetings, feedback from clinicians and information from Sarepta before making the change. Sarepta Chief Executive Doug Ingram said the move was encouraging for children with the disease because it could loosen up strict policies at health insurers who have tight controls on covering the treatment.
Sarepta Therapeutics (SRPT) got some good news today when health insurer Anthem (ANTM) decided to cover the treatment of Sarepta’s drug for Duchenne muscular dystrophy, Exondys 51, in ambulatory patients, ...
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Controversy dimmed the excitement over the FDA’s decision last year to approve Sarepta Therapeutics’s (SRPT) Duchenne muscular dystrophy drug Exondys51. On Saturday, early-stage data regarding golodirsen was released at the 22nd International Annual Congress of the World Muscle Society. Today, some analysts are offering their take on what might be in store for Sarepta and at the FDA.
Sarepta Therapeutics Inc. shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a "compelling argument" for faster-than-normal approval ...
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.